Seipasa is a leading company specialized in natural treatments for agriculture. Seipasa is pioneer in researching, manufacturing and marketing biopesticides, biostimulants and fertilizers. The company has been working for 20 years in natural protection of crops and plant biostimulation based on solutions of botanical origin. From its headquarters in Valencia, Spain, and conducted by the R&D department, the company formulates and certificates solutions of high technological value which are applied in the most demanding agricultures of the world. Seipasa is stablished in over 20 countries worldwide.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research, Industry Outlook

LUMINULTRA LAUNCHES BUGCOUNT® FUEL, A REVOLUTIONARY MICROBIAL TEST FOR FUELS

PRnewswire | July 06, 2023

news image

LuminUltra today announced the launch of BugCount® Fuel, an innovative, user-friendly test kit to quickly and accurately evaluate fuels for microbial contamination which can cause significant challenges for a range of industries including aviation, marine, and fuel handling. Microbiological testing of fuel is critical for identifying and getting ahead of issues that lead to compromised performance, including clogged filters, worn injectors, fuel tank lining (pitting) corrosi...

Read More

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

news image

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More

Diagnostics

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

news image

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More

Cell and Gene Therapy

PERKINELMER COMPLETES ACQUISITION OF ANTIBODY AND REAGENT LEADER BIOLEGEND

PerkinElmer | September 18, 2021

news image

PerkinElmer, Inc.a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion. The acquisition, the largest in PerkinElmer’s history, further expands the Company’s life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant protei...

Read More
news image

Research, Industry Outlook

LUMINULTRA LAUNCHES BUGCOUNT® FUEL, A REVOLUTIONARY MICROBIAL TEST FOR FUELS

PRnewswire | July 06, 2023

LuminUltra today announced the launch of BugCount® Fuel, an innovative, user-friendly test kit to quickly and accurately evaluate fuels for microbial contamination which can cause significant challenges for a range of industries including aviation, marine, and fuel handling. Microbiological testing of fuel is critical for identifying and getting ahead of issues that lead to compromised performance, including clogged filters, worn injectors, fuel tank lining (pitting) corrosi...

Read More
news image

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More
news image

Diagnostics

EVONETIX GRANTED PATENT FOR TECHNOLOGY ENABLING THERMALLY-CONTROLLED DNA SYNTHESIS

evonetix | April 04, 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and u...

Read More
news image

Cell and Gene Therapy

PERKINELMER COMPLETES ACQUISITION OF ANTIBODY AND REAGENT LEADER BIOLEGEND

PerkinElmer | September 18, 2021

PerkinElmer, Inc.a global leader committed to innovating for a healthier world, today announced it has completed its acquisition of BioLegend, a leading, worldwide provider of life science antibodies and reagents for a total consideration of approximately $5.25 billion. The acquisition, the largest in PerkinElmer’s history, further expands the Company’s life science franchise into high-growth areas such as cytometry, proteogenomics, multiplex assays, recombinant protei...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us